{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:16:40Z","timestamp":1792678600899,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR-072615"],"award-info":[{"award-number":["R01 AR-072615"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","award":["Graduate Student Preceptorship"],"award-info":[{"award-number":["Graduate Student Preceptorship"]}],"id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","award":["Preceptership Award"],"award-info":[{"award-number":["Preceptership Award"]}],"id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"DOI":"10.1038\/s41423-026-01386-y","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T01:02:27Z","timestamp":1769734947000},"page":"315-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["TWEAK receptor (Fn14) exacerbates TNF-\u03b1-induced inflammation in rheumatoid arthritis synovial fibroblasts and influences response to anti-TNF-\u03b1 therapy"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7181-638X","authenticated-orcid":false,"given":"Farheen S.","family":"Shaikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena A.","family":"Shanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4102-2420","authenticated-orcid":false,"given":"Anil K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis M.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadik A.","family":"Khuder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey M.","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios A.","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"O\u2019Dell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu M.","family":"Ouseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2526-8110","authenticated-orcid":false,"given":"Salahuddin","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"1386_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18053\/jctres.02.201603.005","volume":"2","author":"M Farrugia","year":"2016","unstructured":"Farrugia M, Baron B. The role of TNF-\u03b1 in rheumatoid arthritis: a focus on regulatory T cells. J Clin Transl Res. 2016;2:84\u201390.","journal-title":"J Clin Transl Res"},{"key":"1386_CR2","doi-asserted-by":"crossref","unstructured":"Jang D-I, Lee AH, Shin H-Y, Song H-R, Park J-H, Kang T-B, et al. The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. 2021;22:2719.","DOI":"10.3390\/ijms22052719"},{"key":"1386_CR3","doi-asserted-by":"crossref","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.","DOI":"10.1038\/nrdp.2018.1"},{"key":"1386_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrrheum.2009.181","volume":"5","author":"PC Taylor","year":"2009","unstructured":"Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5:578\u201382.","journal-title":"Nat Rev Rheumatol"},{"key":"1386_CR5","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/jcm12041630","volume":"12","author":"GM Leone","year":"2023","unstructured":"Leone GM, Mangano K, Petralia MC, Nicoletti F, Fagone P. Past, present and (foreseeable) future of biological anti-TNF alpha therapy. J Clin Med. 2023;12:1630.","journal-title":"J Clin Med"},{"key":"1386_CR6","doi-asserted-by":"publisher","first-page":"1759720","DOI":"10.1177\/1759720X221114101","volume":"14","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Matucci Cerinic M, Alten R, Avouac J, Westhovens R. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimizing treatment outcomes. Ther Adv Musculoskelet Dis. 2022;14:1759720\u2013X221114101.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1386_CR7","doi-asserted-by":"crossref","unstructured":"Rubbert-Roth A, Szab\u00f3 MZ, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents. Autoimmun Rev. 2019;18:102398.","DOI":"10.1016\/j.autrev.2019.102398"},{"key":"1386_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13075-020-2122-5","volume":"22","author":"S Ochi","year":"2020","unstructured":"Ochi S, Saito K, Mizoguchi F, Kato S, Tanaka Y. Insensitivity versus poor response to tumor necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. Arthritis Res Ther. 2020;22:41.","journal-title":"Arthritis Res Ther"},{"key":"1386_CR9","doi-asserted-by":"crossref","unstructured":"Ogawa Y, Takahashi N, Kaneko A, Hirano Y, Kanayama Y, Yabe Y, et al. Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis. Clin Rheumatol. 2019;38:2757\u201363.","DOI":"10.1007\/s10067-019-04626-x"},{"key":"1386_CR10","doi-asserted-by":"crossref","unstructured":"Johnson KJ, Sanchez HN, Schoenbrunner N. Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders. Clin Rheumatol. 2019;38:2967\u201376.","DOI":"10.1007\/s10067-019-04684-1"},{"key":"1386_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H","volume":"50","author":"HT Idriss","year":"2000","unstructured":"Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure\u2012function relationship(s). Microsc Res Tech. 2000;50:184\u201395.","journal-title":"Microsc Res Tech"},{"key":"1386_CR12","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","volume":"49","author":"T Horiuchi","year":"2010","unstructured":"Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49:1215\u201328.","journal-title":"Rheumatology"},{"key":"1386_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/intimm\/dxs047","volume":"24","author":"S Bl\u00fcml","year":"2012","unstructured":"Bl\u00fcml S, Scheinecker C, Smolen JS, Redlich K. Targeting TNF receptors in rheumatoid arthritis. Int Immunol. 2012;24:275\u201381.","journal-title":"Int Immunol"},{"key":"1386_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/ar2974","volume":"12","author":"OJ Arntz","year":"2010","unstructured":"Arntz OJ, Geurts J, Veenbergen S, Bennink MB, van den Brand BT, Abdollahi-Roodsaz S, et al. A crucial role for tumor necrosis factor receptor 1 in synovial lining cells and the reticuloendothelial system in mediating experimental arthritis. Arthritis Res Ther. 2010;12:R61.","journal-title":"Arthritis Res Ther"},{"key":"1386_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/cbin.10735","volume":"41","author":"H Zhang","year":"2017","unstructured":"Zhang H, Xiao W. TNFR1 and TNFR2 differentially mediate TNF-\u03b1-induced inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes. Cell Biol Int. 2017;41:415\u201322.","journal-title":"Cell Biol Int"},{"key":"1386_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cmi.2017.138","volume":"16","author":"V Lamontain","year":"2019","unstructured":"Lamontain V, Schmid T, Weber-Steffens D, Zeller D, Jenei-Lanzl Z, Wajant H, et al. Stimulation of TNF receptor type 2 expands regulatory T cells and ameliorates established collagen-induced arthritis in mice. Cell Mol Immunol. 2019;16:65\u201374.","journal-title":"Cell Mol Immunol"},{"key":"1386_CR17","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41423-022-00913-x","volume":"19","author":"RJ Siegel","year":"2022","unstructured":"Siegel RJ, Singh AK, Panipinto PM, Shaikh FS, Vinh J, Han SU, et al. Extracellular sulfatase-2 is overexpressed in rheumatoid arthritis and mediates the TNF-alpha-induced inflammatory activation of synovial fibroblasts. Cell Mol Immunol. 2022;19:1185\u201395.","journal-title":"Cell Mol Immunol"},{"key":"1386_CR18","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.4049\/jimmunol.148.10.3152","volume":"148","author":"G Kruppa","year":"1992","unstructured":"Kruppa G, Thoma B, Machleidt T, Wiegmann K, Kr\u00f6nke M. Inhibition of tumor necrosis factor (TNF)-mediated NF-kappa B activation by selective blockade of the human 55-kDa TNF receptor. J Immunol. 1992;148:3152\u20137.","journal-title":"J Immunol"},{"key":"1386_CR19","doi-asserted-by":"crossref","unstructured":"DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature. 1997;388:548\u201354.","DOI":"10.1038\/41493"},{"key":"1386_CR20","doi-asserted-by":"crossref","unstructured":"Umar S, Hedaya O, Singh AK, Ahmed S. Thymoquinone inhibits TNF-\u03b1-induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation. Toxicol Appl Pharmacol. 2015;287:299\u2013305.","DOI":"10.1016\/j.taap.2015.06.017"},{"key":"1386_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4049\/jimmunol.170.1.341","volume":"170","author":"M Nakayama","year":"2003","unstructured":"Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, et al. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2003;170:341\u20138.","journal-title":"J Immunol"},{"key":"1386_CR22","first-page":"411","volume":"6","author":"JA Winkles","year":"2008","unstructured":"Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Drug. 2008;6:411\u201325.","journal-title":"Drug"},{"key":"1386_CR23","doi-asserted-by":"crossref","unstructured":"Cheng E, Armstrong CL, Galisteo R, Winkles JA. TWEAK\/Fn14 axis-targeted therapeutics: moving basic science discoveries to the clinic. Front Immunol. 2013;4:473.","DOI":"10.3389\/fimmu.2013.00473"},{"key":"1386_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/ar3294","volume":"13","author":"AA Dharmapatni","year":"2011","unstructured":"Dharmapatni AA, Smith MD, Crotti TN, Holding CA, Vincent C, Weedon HM, et al. TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther. 2011;13:R51.","journal-title":"Arthritis Res Ther"},{"key":"1386_CR25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/rheumatology\/ken006","volume":"47","author":"S Kamijo","year":"2008","unstructured":"Kamijo S, Nakajima A, Kamata K, Kurosawa H, Yagita H, Okumura K. Involvement of TWEAK\/Fn14 interaction in the synovial inflammation of RA. Rheumatology. 2008;47:442\u201350.","journal-title":"Rheumatology"},{"key":"1386_CR26","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.2741\/1395","volume":"9","author":"S Campbell","year":"2004","unstructured":"Campbell S, Michaelson J, Burkly L, Putterman C. The role of TWEAK\/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci. 2004;9:2273\u201384.","journal-title":"Front Biosci"},{"key":"1386_CR27","doi-asserted-by":"crossref","unstructured":"Chorianopoulos E, Heger T, Lutz M, Frank D, Bea F, Katus HA, et al. FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA\/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res Cardiol. 2010;105:301\u201313.","DOI":"10.1007\/s00395-009-0046-y"},{"key":"1386_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3390\/cells9020405","volume":"9","author":"N Mendez-Barbero","year":"2020","unstructured":"Mendez-Barbero N, Gutierrez-Munoz C, Blazquez-Serra R, Martin-Ventura JL, Blanco-Colio LM. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK)\/fibroblast growth factor-inducible 14 (Fn14) axis in cardiovascular diseases: progress and challenges. Cells. 2020;9:405.","journal-title":"Cells"},{"key":"1386_CR29","doi-asserted-by":"crossref","unstructured":"Holmberg R, Robinson M, Gilbert SF, Lujano-Olazaba O, Waters JA, Kogan E, et al. TWEAK-Fn14-RelB Signaling Cascade Promotes Stem Cell-like Features that Contribute to Post-Chemotherapy Ovarian Cancer Relapse. Mol Cancer Res. 2023;21:170\u201386.","DOI":"10.1158\/1541-7786.MCR-22-0486"},{"issue":"6","key":"1386_CR30","doi-asserted-by":"publisher","first-page":"e65248","DOI":"10.1371\/journal.pone.0065248","volume":"8","author":"SA Brown","year":"2013","unstructured":"Brown SA, Cheng E, Williams MS, Winkles JA. TWEAK-independent Fn14 self-association and NF-\u03baB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain. PLoS ONE. 2013;8(6):e65248.","journal-title":"PLoS ONE"},{"key":"1386_CR31","doi-asserted-by":"crossref","unstructured":"Wisniacki N, Amaravadi L, Galluppi GR, Zheng TS, Zhang R, Kong J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis. Clin Ther. 2013;35:1137\u201349.","DOI":"10.1016\/j.clinthera.2013.06.008"},{"key":"1386_CR32","doi-asserted-by":"publisher","first-page":"117440","DOI":"10.1016\/j.lfs.2020.117440","volume":"247","author":"SD Unudurthi","year":"2020","unstructured":"Unudurthi SD, Nassal DM, Patel NJ, Thomas E, Yu J, Pierson CG, et al. Fibroblast growth factor-inducible 14 mediates macrophage infiltration in heart to promote pressure overload-induced cardiac dysfunction. Life. 2020;247:117440\u20139.","journal-title":"Life"},{"key":"1386_CR33","doi-asserted-by":"crossref","unstructured":"Gupta RK, Gracias DT, Figueroa DS, Miki H, Miller J, Fung K, et al. TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy. Sci Immunol. 2021;6:eabi8823.","DOI":"10.1126\/sciimmunol.abi8823"},{"key":"1386_CR34","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1136\/ard-2023-224476","volume":"82","author":"S Lillegraven","year":"2023","unstructured":"Lillegraven S, Paulshus Sundlis\u00e6ter N, Aga AB, Sexton J, Olsen IC, Lexberg \u00c5, et al. Effect of tapered versus stable treatment with tumor necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomized, open label, noninferiority trial. Ann Rheum Dis. 2023;82:1394\u2013403.","journal-title":"Ann Rheum Dis"},{"key":"1386_CR35","doi-asserted-by":"crossref","unstructured":"Khader Y, Beran A, Ghazaleh S, Lee-Smith W, Altorok N. Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis. Clin Rheumatol. 2022;41:3615\u201327.","DOI":"10.1007\/s10067-022-06307-8"},{"key":"1386_CR36","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","volume":"45","author":"KL Hyrich","year":"2006","unstructured":"Hyrich KL, Watson KD, Silman AJ, Symmons DPM. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology. 2006;45:1558\u201365.","journal-title":"Rheumatology"},{"key":"1386_CR37","first-page":"222","volume":"25","author":"MM Ward","year":"2023","unstructured":"Ward MM, Madanchi N, Yazdanyar A, Shah NR, Constantinescu F. Prevalence and predictors of sustained remission\/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review. Arthritis. 2023;25:222.","journal-title":"Arthritis"},{"key":"1386_CR38","doi-asserted-by":"crossref","unstructured":"Naniwa T, Iwagaitsu S, Kajiura M. Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: An observational study in routine clinical care. Mod Rheumatol. 2020;30:948\u201358.","DOI":"10.1080\/14397595.2019.1702253"},{"key":"1386_CR39","doi-asserted-by":"crossref","unstructured":"Park JS, Kwok SK, Lim MA, Oh HJ, Kim EK, Jhun JY, et al. TWEAK promotes osteoclastogenesis in rheumatoid arthritis. Am J Pathol. 2013;183:857\u201367.","DOI":"10.1016\/j.ajpath.2013.05.027"},{"key":"1386_CR40","doi-asserted-by":"crossref","unstructured":"Murat KARKUCAK, Erhan \u00c7APKIN, Ha\u015fim \u00c7AKIRBAY, Ay\u015fe AKY\u00dcZ, Ahmet ALVER, Ay\u015feg\u00fcl CANSU, et al. Serum Levels of Anti-Citrullinated Protein Antibody (ACPA) and TWEAK in Patients with Rheumatoid Arthritis: Association with Disease Activity and Treatment Modalities. Arch Rheumatol. 2011;26:204\u20137.","DOI":"10.5606\/tjr.2011.032"},{"key":"1386_CR41","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.4049\/jimmunol.1600360","volume":"197","author":"N Akhtar","year":"2016","unstructured":"Akhtar N, Singh AK, Ahmed S. MicroRNA-17 suppresses TNF-\u03b1 signaling by interfering with TRAF2 and cIAP2 association in rheumatoid arthritis synovial fibroblasts. J Immunol. 2016;197:2219\u201328.","journal-title":"J Immunol"},{"key":"1386_CR42","doi-asserted-by":"crossref","unstructured":"Fechtner S, Singh AK, Srivastava I, Szlenk CT, Muench TR, Natesan S, et al. Cannabinoid receptor 2 agonist JWH-015 inhibits interleukin-1\u03b2-induced inflammation in rheumatoid arthritis synovial fibroblasts and in adjuvant induced arthritis rat via glucocorticoid receptor. Front Immunol. 2019;10:1027.","DOI":"10.3389\/fimmu.2019.01027"},{"key":"1386_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1285455","volume":"14","author":"Y Bian","year":"2023","unstructured":"Bian Y, Xiang Z, Wang Y, Ren Q, Chen G, Xiang B, et al. Immunomodulatory roles of metalloproteinases in rheumatoid arthritis. Front Pharmacol. 2023;14:1285455.","journal-title":"Front Pharmacol"},{"key":"1386_CR44","doi-asserted-by":"crossref","unstructured":"Dhruv H, Loftus JC, Narang P, Petit JL, Fameree M, Burton J, et al. Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis. J Biol Chem. 2013;288:32261\u201376.","DOI":"10.1074\/jbc.M113.493536"},{"key":"1386_CR45","doi-asserted-by":"crossref","unstructured":"Brightbill HD, Suto E, Blaquiere N, Ramamoorthi N, Sujatha-Bhaskar S, Gogol EB, et al. NF-\u03baB inducing kinase is a therapeutic target for systemic lupus erythematosus. Nat Commun. 2018;9:179.","DOI":"10.1038\/s41467-017-02672-0"},{"key":"1386_CR46","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.4049\/jimmunol.2300762","volume":"212","author":"C Matellan","year":"2024","unstructured":"Matellan C, Kennedy C, Santiago-Vela MI, Hochegger J, N\u00ed Chathail MB, Wu A,\u00a0et al. The TNFSF12\/TWEAK Modulates Colonic Inflammatory Fibroblast Differentiation and Promotes Fibroblast-Monocyte Interactions. J Immunol. 2024;212:1958\u201370.","journal-title":"J Immunol"},{"key":"1386_CR47","doi-asserted-by":"crossref","unstructured":"Cherry EM, Lee DW, Jung JU, Sitcheran R. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-\u03baB-inducing kinase (NIK) and noncanonical NF-\u03baB signaling. Mol Cancer. 2015;14:9.","DOI":"10.1186\/s12943-014-0273-1"},{"key":"1386_CR48","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3389\/fimmu.2017.01970","volume":"8","author":"M Metzemaekers","year":"2018","unstructured":"Metzemaekers M, Vanheule V, Janssens R, Struyf S, Proost P. Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands. Front Immunol. 2018;8:1970.","journal-title":"Front Immunol"},{"key":"1386_CR49","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3899\/jrheum.090769","volume":"37","author":"WP Kuan","year":"2010","unstructured":"Kuan WP, Tam LS, Wong CK, Ko FW, Li T, Zhu T,\u00a0et al. CXCL 9 and CXCL 10 as Sensitive markers of disease activity in patients with rheumatoid arthritis. J Rheumatol. 2010;37:257\u201364.","journal-title":"J Rheumatol"},{"key":"1386_CR50","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/art.41611","volume":"73","author":"M Haque","year":"2021","unstructured":"Haque M, Singh AK, Ouseph MM, Ahmed S. Regulation of synovial inflammation and tissue destruction by guanylate binding protein 5 in synovial fibroblasts from patients with rheumatoid arthritis and rats with adjuvant-induced arthritis. Arthritis Rheumatol. 2021;73:943\u201354.","journal-title":"Arthritis Rheumatol"},{"key":"1386_CR51","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/annrheumdis-2014-205809","volume":"75","author":"K Klein","year":"2016","unstructured":"Klein K, Kabala PA, Grabiec AM, Gay RE, Kolling C, Lin LL,\u00a0et al. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis. 2016;75:422\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1386_CR52","doi-asserted-by":"publisher","first-page":"1079851","DOI":"10.1155\/2016\/1079851","volume":"2016","author":"JM Gane","year":"2016","unstructured":"Gane JM, Stockley RA, Sapey E. TNF-\u03b1 Autocrine Feedback Loops in Human Monocytes: The Pro- and Anti-Inflammatory Roles of the TNF-\u03b1 Receptors Support the Concept of Selective TNFR1 Blockade In Vivo. J Immunol Res. 2016;2016:1079851.","journal-title":"J Immunol Res"},{"key":"1386_CR53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0165-2478(02)00079-2","volume":"83","author":"J Youn","year":"2002","unstructured":"Youn J, Kim H-Y, Park JH, Hwang S-H, Lee SY, Cho C-S, et al. Regulation of TNF-\u03b1-mediated hyperplasia through TNF receptors, TRAFs, and NF-\u03baB in synoviocytes obtained from patients with rheumatoid arthritis. Immunol Lett. 2002;83:85\u201393.","journal-title":"Immunol Lett"},{"key":"1386_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.901437","volume":"13","author":"T Iwasaki","year":"2022","unstructured":"Iwasaki T, Watanabe R, Ito H, Fujii T, Okuma K, Oku T, et al. Dynamics of type I and type II interferon signature determines responsiveness to anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2022;13:901437.","journal-title":"Front Immunol"},{"key":"1386_CR55","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.3389\/fimmu.2017.02007","volume":"8","author":"J Rodr\u00edguez-Carrio","year":"2017","unstructured":"Rodr\u00edguez-Carrio J, Alperi-L\u00f3pez M, L\u00f3pez P, Ballina-Garc\u00eda FJ, Su\u00e1rez A. Heterogeneity of the Type I Interferon Signature in Rheumatoid Arthritis: A Potential Limitation for Its Use As a Clinical Biomarker. Front Immunol. 2018;8:2007.","journal-title":"Front Immunol"},{"key":"1386_CR56","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1073\/pnas.0408506102","volume":"102","author":"AK Palucka","year":"2005","unstructured":"Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA. 2005;102:3372\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1386_CR57","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1002\/art.38095","volume":"65","author":"BA Jones","year":"2013","unstructured":"Jones BA, Riegsecker S, Rahman A, Beamer M, Aboualaiwi W, Khuder SA, et al. Role of ADAM-17, p38 MAPK, cathepsins, and the proteasome pathway in the synthesis and shedding of fractalkine\/CX\u2083 CL1 in rheumatoid arthritis. Arthritis Rheum. 2013;65:2814\u201325.","journal-title":"Arthritis Rheum"},{"key":"1386_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755844","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Huang J, Xie D, He D, Lu A, Liang C. Toward overcoming treatment failure in rheumatoid arthritis. Front Immunol. 2021;12:755844.","journal-title":"Front Immunol"},{"issue":"9","key":"1386_CR59","doi-asserted-by":"publisher","first-page":"e0162316","DOI":"10.1371\/journal.pone.0162316","volume":"11","author":"GP Eng","year":"2016","unstructured":"Eng GP, Bouchelouche P, Bartels EM, Bliddal H, Bendtzen K, Stoltenberg M. Anti-drug antibodies, drug levels, interleukin-6 and soluble TNF receptors in rheumatoid arthritis patients during the first 6 months of treatment with adalimumab or infliximab: a descriptive cohort study. PLoS ONE. 2016;11(9):e0162316.","journal-title":"PLoS ONE"},{"key":"1386_CR60","doi-asserted-by":"crossref","unstructured":"Mikacic M, Kumric M, Baricevic M, Tokic D, Stojanovic Stipic S, Cvitkovic I, et al. Dynamic of Serum TWEAK Levels in Critically Ill COVID-19 Male Patients. J Clin Med. 2022;11:3699.","DOI":"10.3390\/jcm11133699"},{"key":"1386_CR61","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1097\/HEP.0000000000000026","volume":"77","author":"C Short","year":"2023","unstructured":"Short C, Zhong A, Xu J, Mahdi E, Glazier A, Malkoff N, et al. TWEAK\/FN14 promotes profibrogenic pathway activation in Prominin-1-expressing hepatic progenitor cells in biliary atresia. Hepatology. 2023;77:1639\u201353.","journal-title":"Hepatology"},{"key":"1386_CR62","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/1535-7163.MCT-17-0330","volume":"17","author":"ET Lam","year":"2018","unstructured":"Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O\u2019Bryant CL, Ramanathan RK, et al. Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors. Mol Cancer Ther. 2018;17:215\u201321.","journal-title":"Mol Cancer Ther"},{"key":"1386_CR63","unstructured":"Xia Y, Herlitz LC, Gindea S, Wen J, Pawar RD, Misharin A, et al. Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis."},{"key":"1386_CR64","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cyto.2005.12.005","volume":"33","author":"MR Chac\u00f3n","year":"2006","unstructured":"Chac\u00f3n MR, Richart C, G\u00f3mez JM, Meg\u00eda A, Vilarrasa N, Fern\u00e1ndez-Real JM, et al. Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. Cytokine. 2006;33:129\u201337.","journal-title":"Cytokine"},{"key":"1386_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/mr\/road033","volume":"34","author":"R Caporali","year":"2023","unstructured":"Caporali R, Conti F, Iannone F. Management of patients with inflammatory rheumatic diseases after treatment failure with a first tumor necrosis factor inhibitor: a narrative review. Mod Rheumatol. 2023;34:11\u201326.","journal-title":"Mod Rheumatol"},{"key":"1386_CR66","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1080\/13696998.2016.1275653","volume":"20","author":"B Chastek","year":"2017","unstructured":"Chastek B, Becker LK, Chen C-I, Mahajan P, Curtis JR. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. J Med Econ. 2017;20:464\u201373.","journal-title":"J Med Econ"},{"key":"1386_CR67","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41423-019-0284-3","volume":"18","author":"AK Singh","year":"2021","unstructured":"Singh AK, Haque M, O\u2019Sullivan K, Chourasia M, Ouseph MM, Ahmed S. Suppression of monosodium urate crystal-induced inflammation by inhibiting TGF-\u03b2-activated kinase 1-dependent signaling: role of the ubiquitin proteasome system. Cell Mol Immunol. 2021;18:162\u201370.","journal-title":"Cell Mol Immunol"},{"key":"1386_CR68","doi-asserted-by":"crossref","unstructured":"Haque M, Singh AK, Ouseph MM, Ahmed S. Regulation of Synovial Inflammation and Tissue Destruction by Guanylate Binding Protein 5 in Synovial Fibroblasts From Patients With Rheumatoid Arthritis and Rats With Adjuvant-Induced Arthritis. Arthritis Rheumatol. 2021;73:943\u201354.","DOI":"10.1002\/art.41611"},{"key":"1386_CR69","unstructured":"Diller M, Hasseli R, H\u00fclser M-L, Aykara I, Frommer K, Rehart S, et al. Targeting activated synovial fibroblasts in rheumatoid arthritis by peficitinib."},{"key":"1386_CR70","doi-asserted-by":"publisher","first-page":"eadk3506","DOI":"10.1126\/scitranslmed.adk3506","volume":"16","author":"Z Bai","year":"2024","unstructured":"Bai Z, Bartelo N, Aslam M, Murphy EA, Hale CR, Blachere NE, et al. Synovial fibroblast gene expression is associated with sensory nerve growth and pain in rheumatoid arthritis. Sci Transl Med. 2024;16:eadk3506\u2013eadk.","journal-title":"Sci Transl Med"},{"key":"1386_CR71","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/art.22023","volume":"54","author":"S Ahmed","year":"2006","unstructured":"Ahmed S, Pakozdi A, Koch AE. Regulation of interleukin-1\u03b2\u2013induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. Arthritis. 2006;54:2393\u2013401.","journal-title":"Arthritis"},{"key":"1386_CR72","unstructured":"Agere SA, Akhtar N, Watson JM, Ahmed S. RANTES\/CCL5 induces collagen degradation by activating MMP-1 and MMP-13 expression in human rheumatoid arthritis synovial fibroblasts."},{"key":"1386_CR73","doi-asserted-by":"crossref","unstructured":"Panipinto PM, Singh AK, Shaikh FS, Siegel RJ, Chourasia M, Ahmed S. Takinib Inhibits Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts by Targeting the Janus Kinase-Signal Transducer and Activator of Transcription 3 (JAK\/STAT3) Pathway. Int J Mol Sci. 2021;22:12580.","DOI":"10.3390\/ijms222212580"},{"key":"1386_CR74","doi-asserted-by":"crossref","unstructured":"Pappas DA, Kremer JM, Reed G, Greenberg JD, Curtis JR. Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients. BMC. 2014;15:113.","DOI":"10.1186\/1471-2474-15-113"},{"key":"1386_CR75","unstructured":"Kremer JM. The Corrona US registry of rheumatic and autoimmune diseases."},{"key":"1386_CR76","doi-asserted-by":"crossref","unstructured":"Curtis JR, Yang S, Chen L, Pope JE, Keystone EC, Haraoui B, et al. Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis. Arthritis. 2015;67:1345\u201353.","DOI":"10.1002\/acr.22606"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01386-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T23:02:49Z","timestamp":1772233369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01386-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1038\/s41423-026-01386-y","relation":{},"ISSN":["2042-0226"],"issn-type":[{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}